

GLP2-T

PEPTIDES

IMPORTANT: Read This Before Proceeding With Dosing Go to the Prep & Injection Guide for proper reconstitution, syringe sizing, and injection protocols. Mistakes here can compromise your research. the Prep & Injection Guide GLP2-T was originally developed to t

IMPORTANT: Read This Before Proceeding With Dosing Go to the Prep & Injection Guide for proper reconstitution, syringe sizing, and injection protocols. Mistakes here can compromise your research. the Prep & Injection Guide GLP2-T was originally developed to treat Type-2 diabetes but has since become a leading anti-obesity medication. It is a dual agonist of the GLP-1 and GIP receptors — meaning it activates two distinct hormonal pathways to reduce appetite, improve metabolic rate, and support sustained weight loss. Unlike its predecessor GLP1-S (which only targets GLP-1), GLP2-T showed 5–7% more weight loss in clinical trials. Compared to GLP3-R, a triple agonist, GLP2-T accomplished nearly the same weight loss but over a longer period (72 weeks vs. 48). **MECHANISM OF ACTION** GLP-1 : Suppresses appetite and increases feelings of fullness after eating. GIP : Promotes insulin secretion and supports energy balance through receptors in the hypothalamus. **BENEFITS** Average weight loss of 24.7% after 72 weeks Reduces appetite and cravings Enhances satiety and energy balance Supports fat oxidation and metabolism Improves insulin sensitivity and blood sugar control **POSSIBLE SIDE EFFECTS** (often mild and temporary; affected only ~25% in trials) Injection site reaction (redness, swelling, itching) Nausea Vomiting Diarrhea Constipation Decreased appetite Fatigue Dyspepsia (indigestion) Abdominal pain Burping (may have sulfur smell) Hair loss **RARE BUT SERIOUS RISKS** Thyroid C-Cell Tumors Pancreatitis Gastroparesis (stomach paralysis) Hypoglycemia (if used with insulin) Gallbladder disease Kidney issues (linked to dehydration) Pulmonary aspiration under anesthesia – **ALWAYS** disclose GLP2-T use to surgical teams **INTERACTIONS** Insulin and Insulin-stimulating drugs: includes all forms of insulin, sulfonylureas (glipizide, glyburide, glimepiride), and glinides (repaglinide), due to the increased risk of hypoglycemia Oral medications: GLP2-T may interfere the absorption of oral medications Oral birth control medications: increases the likelihood of additive GI effects, may lead to excessive appetite suppression, and increases the risk of hypoglycemia Growth hormone/GH analogs: interactions have been reported with Somatropin, Lonaepsomatropin, Somapacitan Alcohol: increases the risk of hypoglycemia and worsens nausea and dehydration Dehydration risk: dehydration places excessive stress on the kidneys, and may lead to kidney damage; this risk increases with concurrent use with ACE inhibitors, diuretics, ARB's, and heart failure regimens Berberine/Metformin: increased risk of hypoglycemia Chromium/Insulin Sensitizers: increased risk of hypoglycemia Appetite suppressants: added risk of eating disorder/anorexia Stimulants: excessively diminished appetite and GI intolerance overlap Large, greasy meals: increases the likelihood of nausea **PEPTIDE INTERACTIONS SEVERE** Other GLP peptides: Receptor redundancy and desensitization Tesamorelin: Elevated glucose levels IGF-1 LR3/DES and strong ghrelin agonists (e.g. GHRP 2 and 6): may oppose or significantly

amplify GLP2-T's metabolic signaling MODERATE IGF-1 LR3 and IGF-1 DES: Risk of hypoglycemia and rapid glucose uptake CJC WITH DAC: Blunts GLP metabolic benefit GHRP-2, GHRP-6, Hexarelin: Can counter appetite suppression BAM-15: Watch appetite suppression and fatigue LL-37: May worsen nausea and inflammation Oxytocin: Monitor excessive appetite loss CONTRAINDICATIONS Do not use if pregnant or breastfeeding Do not use with a personal or family history of Medullary Thyroid Carcinoma or MEN 2 (Multiple Endocrine Neoplasia) Do not use if you have Type-1 diabetes, diabetic retinopathy, or severe GI disease Do not use if you are allergic or hypersensitive to GLP2-T If you have never taken ANY GLP : Your starting dose is 2.5mg * If you have previously taken any GLP for at least one month at the standard starter/adaptive dose, no matter how much time has elapsed since: Your starting dose is 5mg RECONSTITUTION, DOSING, & RELATED INFO GLP2-T: 10MG RECONSTITUTION Mix with 0.5mL (50 units) of BAC water Dose once per week (every 7 days), always on the same day of the week You must remain on each dose for a minimum of 4 weeks before moving to the next dose May be taken at any time of day/night It is not necessary to be in a fasted state to dose 2.5mg = 12 units 5 mg = 25 units 7.5mg = 36 units 10mg = 50 units GLP2-T: 30MG RECONSTITUTION Mix with 1.5mL (150 units) of BAC water Dose once per week (every 7 days), always on the same day of the week You must remain on each dose for a minimum of 4 weeks before moving to the next dose May be taken at any time of day/night It is not necessary to be in a fasted state to dose Subcutaneous Administration 2.5mg = 12 units 5 mg = 25 units 7.5mg = 36 units 10mg = 50 units 12.5mg = 62 units 15mg = 75 units GLP2-T: 60MG RECONSTITUTION 60MG Mix with 2.5mL (250 units) of BAC water Dose once per week (every 7 days), always on the same day of the week You must remain on each dose for a minimum of 4 weeks before moving to the next dose May be taken at any time of day/night It is not necessary to be in a fasted state to dose Subcutaneous Administration 2.5mg = 10 units 5 mg = 21 units 7.5mg = 31 units 10mg = 42 units 12.5mg = 52 units 15mg = 62 units STACKING SUGGESTIONS AOD-9604 – enhances fat breakdown and further accelerates weight loss alongside appetite suppression Tesamorelin – synergistic for fat reduction, especially visceral fat and metabolic regulation Semax or Selank – manage mood and cognitive function while adjusting to appetite changes NAD+ or MOTS-C – support energy, mitochondrial efficiency, and metabolism while on a caloric deficit BPC-157 – beneficial for gut repair if experiencing nausea, indigestion, or stomach discomfort CJC-1295 / Ipamorelin – for muscle maintenance and enhanced metabolic recovery while losing fat

RESEARCH USE DISCLAIMER: All information in this document is provided strictly for laboratory research and educational purposes. It is not intended for human or veterinary use, diagnosis, or treatment.